Syquant Capital SAS’s Trillium Therapeutics Inc. TRIL Stock Holding History

Syquant Capital SAS’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-50,000	Closed	-$878K	–	57
2021 Q3	$878K	Buy	+50,000	New	+$584K	0.54%	24

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Syquant Capital SAS's TRIL Position: Q4 2021 in Review

Syquant Capital SAS sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 50,000 shares — an estimated $878K sold.

Syquant Capital SAS first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $878K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Syquant Capital SAS reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Syquant Capital SAS sold 50,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $878K.
Syquant Capital SAS first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Syquant Capital SAS's Trillium Therapeutics Inc. position peaked at $878K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Syquant Capital SAS's 13F filing for Q4 2021, filed 12 Jan 2022.